logo
The Evolution Of Timekeeping: From Sundials To MEMS

The Evolution Of Timekeeping: From Sundials To MEMS

Forbes2 days ago

Markus Lutz is CTO and Founder of SiTime Corporation. He is a MEMS expert, a prolific entrepreneur and inventor who holds over 100 patents.
If there is one thing that modern society has in common with its ancient ancestors, it is the desire to measure time. Whether it's finding common ground between daylight saving time and standard time or tracking the sun's movement, humans have always looked for ways to develop timekeeping methods and track seasons, whether for agricultural reasons or religious celebrations.
Scientists refer to this need to measure time as time consciousness, and humans have been chasing this need to track the hours and seasons for more than 5,000 years. One of the earliest signs of timekeeping was discovered in 2013 when researchers found an ancient sundial in Egypt's Valley of the Kings.
Over the millennia, the ability to measure time has become increasingly precise, driven by technological and societal advancements that have shaped the rise of civilizations around the world. If sundials revolutionized time measurement in the 1400s BC, quartz brought timekeeping into the 20th century and silicon brought it into the 21st century.
The Role Of Precision Time Measurement
Modern time measurement is dependent on oscillators, which work as the heartbeat of the clock.
The earliest clocks to use mechanical oscillators were pendulum clocks, based on observations recorded by Galileo. The first successful pendulum clock was built in 1657 and improved precision from minutes to mere seconds per day. For the first time, mechanical clocks became more reliable than the astronomical observations that had been used for centuries and generally lost 15 seconds per day.
In the 1880s, brothers Pierre and Jacques Curie discovered that quartz crystals can generate a consistent electrical signal when subjected to mechanical stress. It took until 1927 to see the invention of the quartz crystal oscillator and the ability to apply an electric charge to induce precise vibrations at a stable frequency. Quartz crystal resonators harnessed this effect, and the new quartz clock provided a level of consistency far superior to mechanical timekeepers.
By the 1970s, quartz technology dominated electronic timekeeping, powering wristwatches, household clocks, computers and telecommunications systems—where precise synchronization was crucial.
In the never-ending search for the most accurate and precise time measurement system, researchers began to explore silicon microelectromechanical systems (MEMS) as a replacement for quartz, given how susceptible it can be to environmental stressors, including temperature, vibration and shock.
By the early 21st century, silicon MEMS oscillators began being commercialized, building a new foundation of precision timing solutions offered by companies like Microchip, Texas Instruments, Analog Devices and SiTime, where I am the founder and CTO.
Advantages Of Silicon MEMS Technology
MEMS starts with the word micro, and this offers an advantage over crystal oscillators. In this case, a silicon MEMS can create oscillators the size of small semiconductor chips. The small size means the ability to be used in more applications, creating more timekeeping devices. Silicon is also more customizable and scalable than crystal and is manufactured to meet very specific demands.
Silicon MEMS is also more environmentally resistant. As mentioned, quartz oscillators are susceptible to extreme temperature changes and other factors. More locations are now vulnerable to these extreme shifts—40- or 50-degree swings in temperature in a matter of hours are not uncommon. An increasing number of devices that rely on time measurement also rely on infrastructure like cell towers that are impacted by extreme weather.
However, it isn't just the outside environment. Because of the energy consumption required by servers, data centers generate a lot of heat that impacts the performance quality of oscillators. The same scenario applies to industrial plants with high-tech machinery that produce excessive heat. At the other extreme, the aerospace and defense industries need to battle temperatures that plunge hundreds of degrees below zero while ensuring that the time measurement systems in airplanes, satellites and rockets remain accurate.
Transitioning To New Applications And Innovations
AI and edge computing are the buzz in technology right now because they are changing the way we do everything. Both AI and edge computing require precision timing technologies, and silicon-based MEMS clocks and oscillators can play a pivotal role in the synchronization of systems.
Quartz-based device oscillators have played an important role in timekeeping for nearly 100 years, but quartz's limitations and inability to remain accurate outside of stable environmental conditions make it a less desirable choice for a variety of electronic systems.
It comes down to this one bit of research: Crystal oscillators have a mean time between failure of approximately 30 million hours, while silicon MEMS is reliable for over 500 million hours. This suggests MEMS-based timing solutions can offer longer operational lifespans in some use cases like AI, edge computing and autonomous systems.
Advances in technology to support AI and edge computing will likely drive a shift away from quartz timing and begin the era of silicon MEMS and precision timing.
Key Considerations When Selecting Precision Timing Devices
While silicon MEMS timing solutions bring notable benefits in areas like reliability, size and environmental robustness, quartz technology continues to play an important role in specific use cases.
For example, quartz oscillators may offer lower phase noise at certain frequencies and remain a practical choice for maintaining compatibility with legacy systems. Additionally, their established presence in global supply chains can make them a cost-efficient option for high-volume, less performance-intensive applications.
As timing technologies evolve, selecting the right solution depends on the unique demands of each design.
Choosing the right precision timing components is critical to system performance and reliability. Key factors to evaluate include frequency stability, phase noise, jitter, power consumption, size, temperature tolerance, cost, underlying technology and supplier support.
A highly stable frequency ensures consistent accuracy across varying conditions, while low phase noise and jitter are essential for reliable performance and precise data synchronization. Low power consumption is vital for energy efficiency, especially in portable or thermally constrained designs, and compact form factors are preferred for space-limited applications.
Finally, selecting a trusted supplier with strong technical support and long-term availability ensures continuity throughout the product lifecycle.
By carefully weighing these parameters, designers can choose timing solutions that deliver long-term accuracy, synchronization and operational reliability.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Business Wire

time3 hours ago

  • Business Wire

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). 'The receipt of Rare Pediatric Disease Designation highlights the significant unmet need that necessitates new therapeutic options for boys living with DMD,' said Cindy Atwell, Chief Development and Business Officer at Precision BioSciences. 'Our first-in-class PBGENE-DMD program, which leverages the differentiated capabilities of our ARCUS gene editing platform to excise exons 45-55 of the dystrophin gene, holds the potential to drive meaningful improvement and durable functional benefit over time for up to 60% of patients with DMD. Our approach is designed to permanently edit a patient's own DNA sequence, resulting in naturally-produced, near full-length dystrophin protein known to be functional in humans. We look forward to completing the final IND-enabling toxicology studies currently underway and generating initial clinical data which is expected in 2026.' The FDA grants Rare Pediatric Disease Designation to therapies targeting serious and life-threatening diseases that affect fewer than 200,000 people in the U.S. and primarily affect individuals under the age of 18. Approximately 15,000 people in the U.S. alone are living with Duchenne muscular dystrophy. With this designation, Precision may be eligible to receive a Priority Review Voucher upon FDA approval of PBGENE-DMD. The Priority Review Voucher program is designed to incentivize drug development for serious rare pediatric diseases. If awarded, a Priority Review Voucher can be redeemed by the original sponsor to receive FDA priority review for a different product. In addition, the Priority Review Voucher can also be sold to a different sponsor, serving as a source of non-dilutive capital to the original sponsor. About PBGENE-DMD PBGENE-DMD is Precision's development program for the treatment of DMD. The approach uses two complementary ARCUS nucleases delivered via a one-time administration in a single AAV to excise exons 45-55 of the dystrophin gene with the aim of restoring near-full length dystrophin protein within the body to improve functional outcomes. PBGENE-DMD is intended to address more than 60% of the DMD patient population. In preclinical studies, PBGENE-DMD demonstrated the ability to target key muscle types involved in the progression of DMD and produced significant, durable functional improvements in a humanized DMD mouse model. PBGENE-DMD restored the body's ability to produce a near full length functional dystrophin protein across multiple muscles, including cardiac tissue and various key skeletal muscle groups. In addition, PBGENE-DMD edited satellite muscle stem cells, believed to be critical for long-term durability and sustained functional improvement. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the DMD program). Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the clinical development and expected safety, efficacy and benefit of our and our partners' and licensees' product candidates and gene editing approaches; the potential of PBGENE-DMD to drive meaningful improvement in functional and durable benefit over time for up to 60% of patients with DMD; the design on PBGENE-DMD to permanently edit a patient's own DNA sequence, resulting in naturally-produced, near full-length dystrophin protein proven known to be functional in humans; the potential value of a Priority Review Voucher(if awarded) including priority review for a different product or sale to another sponsor; the recent sale of a Priority Review Voucher for more than $150 million; the approach of using a single AAV to deliver PBGENE-DMD to excise exons 45-55 of the dystrophin gene with the aim of restoring a near-full length dystrophin protein within the body to improve functional outcomes; the expected timing of regulatory processes and clinical operations (including IND and/or CTA filings, studies, enrollment and clinical data for PBGENE-DMD; and anticipated timing of clinical data. In some cases, you can identify forward-looking statements by terms such as 'aim,' 'anticipate,' 'appear,' 'approach,' 'believe,' , 'confidence', 'contemplate,' 'could,' 'design' 'designed,' 'estimate,' 'expect,' 'goal,' 'intend,' 'look,' 'may,' 'mission,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'pursue,' 'should,' 'strive,' 'suggest,' 'target,' 'will,' 'would,' or the negative thereof and similar words and expressions. Forward-looking statements are based on management's current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim 'top-line' and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption 'Risk Factors' in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at and the Investors page of our website under SEC Filings at All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Ancient ‘pharaoh's curse' could be used to fight cancer: ‘It's up to us to uncover its secrets'
Ancient ‘pharaoh's curse' could be used to fight cancer: ‘It's up to us to uncover its secrets'

Yahoo

time12 hours ago

  • Yahoo

Ancient ‘pharaoh's curse' could be used to fight cancer: ‘It's up to us to uncover its secrets'

From curses to cures — an ancient hex might just be modern science's secret to battling leukemia. In the 1920s, archaeologists blamed a string of bizarre deaths following the excavation of King Tutankhamun's tomb in Egypt on the 'pharaoh's curse.' Decades later, in the 1970s, it happened again when a group of scientists entered the tomb of Casimir IV in Poland. Out of a team of 12, 10 died within weeks. They didn't know it then, but the tomb contained Aspergillus flavus, a fungus that can cause lung infections. Now, University of Pennsylvania researchers have modified this microbial villain and tapped into its potential as a biomedical hero. Their new study — published this week in the journal Nature Chemical Biology — revealed that Aspergillus flavus could transform into a cancer-fighting agent that rivals traditional medicines approved by the Food and Drug Administration. Their work highlights the ability to rebrand a historically toxic substance into a groundbreaking drug. 'Fungi gave us penicillin,' Sherry Gao, an associate professor in chemical and biomolecular engineering and bioengineering, said in a statement, referring to the world's first successful antibiotic. 'These results show that many more medicines derived from natural products remain to be found,' she added. First study author Qiuyue Nie called it an 'unexplored region with tremendous potential.' Gao's group isolated and purified four RiPPs from Aspergillus flavus, with these molecules showing killer results against leukemia cells. But there are obstacles to greater success. 'Purifying these chemicals is difficult,' Nie said. And while scientists have identified thousands of RiPPs in bacteria, far fewer have been found in fungi. This might be in part because researchers used to confuse them with a different class of molecules and didn't fully understand how fungi produced them. 'The synthesis of these compounds is complicated,' Nie noted. 'But that's also what gives them this remarkable bioactivity,' she continued. The new research confirms that much of our environment and nature are not yet fully understood — and this exploration could benefit contemporary medicine. 'Nature has given us this incredible pharmacy,' Gao said. 'It's up to us to uncover its secrets.'

iscore WINS MOST INNOVATIVE DATA SOLUTIONS PROVIDER, EGYPT AT GLOBAL BRAND AWARDS 2024
iscore WINS MOST INNOVATIVE DATA SOLUTIONS PROVIDER, EGYPT AT GLOBAL BRAND AWARDS 2024

Yahoo

timea day ago

  • Yahoo

iscore WINS MOST INNOVATIVE DATA SOLUTIONS PROVIDER, EGYPT AT GLOBAL BRAND AWARDS 2024

LONDON, June 24, 2025 /PRNewswire/ -- iscore, a leading data solutions provider, has been recognised as the "Most Innovative Data Solutions Provider, Egypt, 2024" by Global Brands Magazine (GBM) at the Global Brand Awards. This recognition reflects iscore commitment to enhancing data solutions through innovation. The Global Brand Awards recognises outstanding achievements across various industries worldwide. iscore received this award for its continued efforts in providing effective and reliable data solutions. Jay Reddy, CEO of Global Brands Magazine, commented, "At Global Brands Magazine, we take pride in recognising organizations that drive innovation and excellence. iscore recognition as the Most Innovative Data Solutions Provider in Egypt highlights its dedication to enhancing financial services through advanced data solutions. Their commitment to accuracy, efficiency, and reliability has set a high standard in the industry. Congratulations to iscore team on this well-earned achievement. " ABOUT iscore The Egyptian Credit Bureau - iscore, was founded in 2005 as an Egyptian joint-stock company. Its establishment involved the participation of 25 banks and the Micro, Small, and Medium Enterprises Development Agency (MSMEDA). The Central Bank of Egypt authorized the commencement of its operations on January 22, 2008. The company is dedicated to executing a strategic plan aligned with Egypt's Vision 2030 and the financial inclusion initiative of the Central Bank of Egypt. This involves the incorporation of cutting-edge technologies designed to meet the demands of the digital era. By offering innovative data analysis solutions, iscore assists its clients, which include banks and corporations, in enhancing operational efficiency. Consequently, clients receive the requisite support and accurate data essential for making credit decisions and monitoring business activities to foster sustainability within Egypt financial sector. iscore manages a sophisticated credit database encompassing information on individuals as well as small and medium-sized enterprises (SMEs). Moreover, it provides the capability to verify a diverse range of data by connecting to government databases through the G2G gateway, in accordance with established protocols with various entities. ABOUT GLOBAL BRANDS MAGAZINE (ENGLAND) Global Brands Magazine (GBM) is one of the largest Brands publication in the world, leading the way in delivering insights, news, and opinions on brands shaping the future of their industries. Based in the UK, the magazine keeps readers informed about 'best-in-class' brands worldwide. Each year, GBM recognizes companies that demonstrate innovation, exceptional service, and consumer-focused solutions in their respective industries. With over 8.4 million annual visitors and 14 million page views, GBM is the world's premier Brand magazine. The magazine also boasts a robust social media presence, engagement including 35k+ Facebook followers, 20k+ Instagram followers, 25k+ Twitter followers, and 4k+ LinkedIn followers. ABOUT THE GLOBAL BRAND AWARDS The Global Brand Awards celebrate excellence in brand performance, recognising companies and organisations that excel in quality, innovation, and customer-centric services across various sectors, including finance, education, hospitality, technology, and more. More than 10,000 companies were evaluated in 2024 for the Global Brand Awards. The Global Brand Awards ceremonies are hosted at some of the world's most iconic venues, including The Address Downtown, Waldorf Astoria, Emperors Palace, JW Marriott Marquis, Galaxy Macau, and The Athenee Hotel. Continuing this legacy, this year's event was held at the esteemed Grand Hyatt in Dubai, United Arab Emirates, upholding the tradition of excellence and grandeur. For a complete list of the winners of the Global Brand Awards, please visit: To nominate your company or leader for the Global Brand Awards 2025, visit: Logo: View original content to download multimedia: SOURCE Global Brands Magazine Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store